ISSN 2063-5346
For urgent queries please contact : +918130348310


Main Article Content

Dr Tayyba Irshad, Dr Safeer Ahmad, Dr Sana Abbasi, Khurram Shahzad, Dr. Saba Aliha, Dr Waqas Ahmed, Dr Fahmida Khatoon, Ali Asghar Mirjat,Kashif Lodhi
» doi: 10.53555/ecb/2023.12.12.278


The purpose of the current research was to review the available medical literature to evaluate various therapy options for unidentified interstitial lung disorders. Between 2010 and 2020, the literature was checked out using the Embase, PubMed, Medline, PubMed, and Ovid databases. 15% of individuals with interstitial reparatory disorder diagnosis had unclassifiable interstitial lung illnesses. As a result, it comprises a significant fraction of patients who need to be treated by a specialist team. Due to the variety of patients, unclassified interstitial lung illnesses are more challenging to confirm the diagnosis of than other forms of interstitial lung diseases. A combination of "management" or "treatment" and "unclassified interstitial lung disorders" or "UILD" and "outcome" was included in the search phrases. After this, findings were further narrowed to only include recent original research articles on the management of unclassified interstitial lung disorders. Selected studies included information on the medication's nature and treatment results. 589 studies in all were located. 27 publications were discovered after animal-related studies were excluded and only human trials were included. With a total of 1053 individuals with unexplained interstitial lung diseases, seven articles were determined to be qualified. Four studies—three of which were multi-center—were double-blind, randomized controlled trials. Two studies were case reports, while one research was retrospective. According to the study, nintedanib and pirfenidone (as monotherapy or in combination) are the two most effective treatments for unidentified interstitial lung disorders. It is necessary to conduct more trials with a sound design to investigate prospective intravenous cyclophosphamide and immunotherapy treatments.

Article Details